Drugs / XNW34017
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07327294 | Jan 2026 → Dec 2027 expected | cancer | Evopoint Biosciences Inc. | Not yet recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2026-04-20 | Evopoint Biosciences Inc. | Results 信诺维携多项核心管线最新临床前研究结果亮相2026 AACR evopointbio.com ↗
在多种不同MYC过表达的肿瘤模型中，XNW34017表现出显著优于AURKA抑制剂的肿瘤生长抑制效果。 |
| 2025-11-08 | Evopoint Biosciences Inc. | Regulatory 管线进展丨信诺维口服蛋白降解剂XNW34017获批临床 evopointbio.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-04-20 | Evopoint Biosciences Inc. | 信诺维携多项核心管线最新临床前研究结果亮相2026 AACR evopointbio.com ↗ |
| 2025-11-08 | Evopoint Biosciences Inc. | 管线进展丨信诺维口服蛋白降解剂XNW34017获批临床 evopointbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | XNW34017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07327294 ↗ |
| Route | Oral | “Route of Administration: Oral” NCT07327294 ↗ |